Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Precision BioSciences stock price, quote, forecast and news

DTIL
US74019P1084
A2PGA1

Price

9.94
Today +/-
+0.19
Today %
+2.14 %
P

Precision BioSciences stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Precision BioSciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Precision BioSciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Precision BioSciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Precision BioSciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Precision BioSciences Stock Price History

DatePrecision BioSciences Price
9/6/20249.94 undefined
9/5/20249.73 undefined
9/4/20249.91 undefined
9/3/202410.40 undefined
8/30/202410.88 undefined
8/29/202410.55 undefined
8/28/20249.72 undefined
8/27/20249.71 undefined
8/26/20249.94 undefined
8/23/20249.69 undefined
8/22/20249.72 undefined
8/21/20249.83 undefined
8/20/20248.85 undefined
8/19/20248.95 undefined
8/16/20248.83 undefined
8/15/20248.61 undefined
8/14/20248.96 undefined
8/13/20248.95 undefined
8/12/20248.84 undefined
8/9/20248.58 undefined

Precision BioSciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Precision BioSciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Precision BioSciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Precision BioSciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Precision BioSciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Precision BioSciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Precision BioSciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Precision BioSciences’s growth potential.

Precision BioSciences Revenue, EBIT and net profit per share

DatePrecision BioSciences RevenuePrecision BioSciences EBITPrecision BioSciences Net Income
2030e557.37 M undefined330.45 M undefined14.01 M undefined
2029e44.52 M undefined301.2 M undefined12.76 M undefined
2028e41 M undefined-98.68 M undefined6.34 M undefined
2027e30.22 M undefined-87.92 M undefined3.91 M undefined
2026e11.24 M undefined-78.8 M undefined-47.11 M undefined
2025e15.04 M undefined-74.64 M undefined-59.37 M undefined
2024e81.18 M undefined-48.1 M undefined-10.64 M undefined
202348.73 M undefined-43.74 M undefined-61.32 M undefined
202225.1 M undefined-62.31 M undefined-111.64 M undefined
2021115.53 M undefined-39.38 M undefined-30.6 M undefined
202024.29 M undefined-109.83 M undefined-109.01 M undefined
201922.24 M undefined-87.2 M undefined-92.88 M undefined
201810.88 M undefined-47.91 M undefined-46.04 M undefined
20176.48 M undefined-21.86 M undefined-21.1 M undefined
20167.02 M undefined-8.83 M undefined-8.25 M undefined

Precision BioSciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
761022241152548811511304144557
--14.2966.67120.009.09379.17-78.2692.0068.75-81.48-26.67172.7336.677.321,165.91
---------------
000000000000000
-8-21-47-87-109-39-62-43-48-74-78-87-98301330
-114.29-350.00-470.00-395.45-454.17-33.91-248.00-89.58-59.26-493.33-709.09-290.00-239.02684.0959.25
-8-21-46-92-109-30-111-61-10-59-47361214
-162.50119.05100.0018.48-72.48270.00-45.05-83.61490.00-20.34-106.38100.00100.0016.67
1.631.631.631.41.731.962.933.840000000
---------------
Details

Keystats

ⓘ

Revenue and Growth

The Precision BioSciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Precision BioSciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20162017201820192020202120222023
               
93.4262.8103.19180.8989.8143.66189.58116.68
000.520.97100.490.720.9
000.5000011.9
00000000
0.591.5111.4611.825.7717.68.816.88
94.0264.31115.68193.67105.56161.75199.11136.36
3.548.1421.1539.5741.529.3323.1614.6
000006.844.753.21
000006.887.234.99
0.280.091.471.431.372.051.350.4
00000000
0.190.120.310.561.724.642.570.23
4.018.3522.9341.5644.5949.7439.0623.42
98.0372.66138.6235.23150.16211.5238.17159.78
               
33500011
13.2613.69126.09316.33331.45408.8489.7509.44
-18.01-39.11-85.19-177.07-286.07-316.68-428.31-489.63
00000000
00000000
-4.75-25.4240.91139.2745.3892.1261.3819.81
1.291.812.222.040.791.141.232.97
0.641.483.058.4110.9512.6211.57.67
6.425.918.816.4931.0922.2246.9416.94
000000022.41
00000000
8.349.214.0826.9342.8335.9859.6649.99
000002.4822.220
00000000
94.8289.8584.5769.9962.981.8795.8590.93
94.8289.8584.5769.9962.984.35118.0790.93
103.1699.0598.6496.92105.73120.33177.74140.92
98.4173.63139.55236.19151.11212.45239.12160.73
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Precision BioSciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Precision BioSciences's financial health and stability.

Assets

Precision BioSciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Precision BioSciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Precision BioSciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Precision BioSciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20162017201820192020202120222023
-8-21-46-92-109-30-111-61
01258876
00000000
99-5-10-2-21924-41
0021814-83311
00000002
00000000
92-24-51-71-87-10-45-84
-2-5-15-24-5-5-3-2
-2-5-15-24-5-5-35
00000008
00000000
0003902190
00109136067745
-120107173170945
---2.00-2.00----
-120000000
77-304077-915345-72
90.19-29.74-67.4-95.69-92.42-16.65-49.07-86.39
00000000

Precision BioSciences stock margins

The Precision BioSciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Precision BioSciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Precision BioSciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Precision BioSciences's sales revenue. A higher gross margin percentage indicates that the Precision BioSciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Precision BioSciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Precision BioSciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Precision BioSciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Precision BioSciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Precision BioSciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Precision BioSciences Margin History

Precision BioSciences Gross marginPrecision BioSciences Profit marginPrecision BioSciences EBIT marginPrecision BioSciences Profit margin
2030e0 %59.29 %2.51 %
2029e0 %676.57 %28.66 %
2028e0 %-240.66 %15.47 %
2027e0 %-290.95 %12.93 %
2026e0 %-701.14 %-419.12 %
2025e0 %-496.47 %-394.85 %
2024e0 %-59.25 %-13.11 %
20230 %-89.76 %-125.84 %
20220 %-248.26 %-444.8 %
20210 %-34.08 %-26.49 %
20200 %-452.25 %-448.86 %
20190 %-392.14 %-417.65 %
20180 %-440.25 %-423.02 %
20170 %-337.08 %-325.45 %
20160 %-125.84 %-117.62 %

Precision BioSciences Stock Sales Revenue, EBIT, Earnings per Share

The Precision BioSciences earnings per share therefore indicates how much revenue Precision BioSciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Precision BioSciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Precision BioSciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Precision BioSciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Precision BioSciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Precision BioSciences Revenue, EBIT and net profit per share

DatePrecision BioSciences Sales per SharePrecision BioSciences EBIT per sharePrecision BioSciences Earnings per Share
2030e77.09 undefined0 undefined1.94 undefined
2029e6.16 undefined0 undefined1.76 undefined
2028e5.67 undefined0 undefined0.88 undefined
2027e4.18 undefined0 undefined0.54 undefined
2026e1.55 undefined0 undefined-6.52 undefined
2025e2.08 undefined0 undefined-8.21 undefined
2024e11.23 undefined0 undefined-1.47 undefined
202312.69 undefined-11.39 undefined-15.96 undefined
20228.57 undefined-21.27 undefined-38.1 undefined
202159.06 undefined-20.13 undefined-15.65 undefined
202014.01 undefined-63.34 undefined-62.86 undefined
201915.88 undefined-62.29 undefined-66.34 undefined
20186.66 undefined-29.32 undefined-28.17 undefined
20173.97 undefined-13.38 undefined-12.91 undefined
20164.29 undefined-5.4 undefined-5.05 undefined

Precision BioSciences business model

Precision BioSciences was founded in 2006 in Durham, North Carolina, USA and is a biotech company specializing in the development of genome editing technologies. The company's main products are genomic single-strand cutter (GSSC) enzymes and related solutions that provide advanced ways to edit genomes. Precision BioSciences focuses on creating innovative technologies and partnerships with industrial, scientific, and academic partners. Through the development of new products and expanding its business relationships, Precision BioSciences has built a strong market presence in recent years. Precision BioSciences has two business divisions: Genome Editing and Food. The Genome Editing division is dedicated to developing new technologies for modifying genes in living cells. A key product of this division is ARCUS, a patented gene editing toolkit. ARCUS consists of two main components, a GSSC enzyme and a specific DNA target, and provides detailed, precise, and controlled editing of genomes. The technology offers a high level of flexibility, efficiency, and precision. The Food division focuses on the development of plants in agriculture and serves as an important complement to the Genome Editing division. Precision BioSciences uses advanced technologies like ARCUS to edit the genomics of plants and improve their traits, such as resistance to pests or heat. The company works closely with scientific partners and the agricultural industry to develop innovative solutions for the requirements of modern farming. Precision BioSciences has introduced a range of impressive products that meet the growing demand for genome editing. Some notable products include: CAR T-cell therapy: A revolutionary cancer treatment that uses inactivated virus and ARCUS technology to achieve outstanding results in the treatment of leukemias and lymphomas. Advanced papaya: This technology utilizes ARCUS to produce papayas that have resistance to papaya virus disease. This innovative solution aims to increase crop yields and reduce crop loss. PrecisionXtract: A new service that processes patient data to ensure precise and effective genome editing. This product is designed to meet the requirements of clinical studies and medical procedures while ensuring safety and sustainability. Overall, Precision BioSciences has established its position in the genome editing market thanks to its innovative product line, strong partnerships, and comprehensive knowledge and expertise. With a solid footing in the genome editing market, Precision BioSciences is well-positioned to continue expanding and developing innovative solutions for the genomics of humans, animals, and plants. Precision BioSciences is one of the most popular companies on Eulerpool.com.

Precision BioSciences SWOT Analysis

Strengths

  • Strong Intellectual Property portfolio, providing a competitive advantage in the field of gene editing.
  • Highly skilled research and development team specialized in developing innovative gene editing technologies.
  • Advanced proprietary platform, ARCUS, enables precise and efficient gene editing.
  • Collaborative partnerships with leading academic and commercial organizations, fostering innovation and knowledge sharing.
  • Strong financial position, allowing for investment in research and development and expansion of operations.

Weaknesses

  • Relatively small company size compared to some competitors, potentially limiting resources and market reach.
  • Limited product portfolio, focusing primarily on gene editing tools and technologies.
  • Dependence on third-party partnerships for the development and commercialization of certain products.
  • Regulatory and ethical challenges associated with gene editing technologies may hinder widespread adoption and acceptance.

Opportunities

  • Growing demand for gene editing tools and therapies, driven by advancements in personalized medicine and genetic research.
  • Potential expansion into new markets or collaborations through strategic partnerships.
  • Increasing investments in gene therapy and gene editing technologies by governments, pharmaceutical companies, and venture capitalists.
  • Rising public interest and acceptance of gene editing for potentially curing genetic diseases.

Threats

  • Intense competition from existing and emerging players in the gene editing industry.
  • Stringent regulatory environment and uncertainty surrounding the legal and ethical aspects of gene editing.
  • Rapidly evolving technological landscape, requiring continuous innovation and adaptation.
  • Potential negative public perception and backlash towards gene editing due to ethical concerns and safety risks.

Precision BioSciences Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Precision BioSciences historical P/E ratio, EBIT, and P/S ratio.

Precision BioSciences shares outstanding

The number of shares was Precision BioSciences in 2023 — This indicates how many shares 3.841 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Precision BioSciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Precision BioSciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Precision BioSciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Precision BioSciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Precision BioSciences Stock splits

In Precision BioSciences's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Precision BioSciences.

Precision BioSciences latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-1.54 4.67  (404.21 %)2024 Q2
3/31/2024-1.95 -0.35  (82.07 %)2024 Q1
12/31/2023-2.09 -4.06  (-94.4 %)2023 Q4
9/30/2023-4.97 -2.1  (57.77 %)2023 Q3
6/30/2023-7.47 -3  (59.82 %)2023 Q2
3/31/2023-6.92 -6.9  (0.23 %)2023 Q1
12/31/2022-6.35 -7.8  (-22.84 %)2022 Q4
9/30/2022-0.27 -0.22  (18.61 %)2022 Q3
6/30/2022-0.42 -0.46  (-9.71 %)2022 Q2
3/31/2022-0.55 -0.46  (16.65 %)2022 Q1
1
2
3

Eulerpool ESG Scorecard© for the Precision BioSciences stock

Eulerpool World ESG Rating (EESG©)

52/ 100

🌱 Environment

55

👫 Social

57

🏛️ Governance

44

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees49
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Precision BioSciences list of shareholders

%
Name
Stocks
Change
Date
7.07 % Janus Henderson Investors511,108511,1083/1/2024
6.92 % Perceptive Advisors LLC500,000500,0003/5/2024
5.72 % Novartis Pharma AG413,581011/15/2023
5.33 % Aquilo Capital Management, LLC385,440385,4403/1/2024
2.95 % Tang Capital Management, LLC213,333100,0001/24/2024
2.36 % Capital World Investors170,649-53,18612/31/2023
2.19 % The Vanguard Group, Inc.158,4932,05712/31/2023
1.87 % Jantz (Derek)135,172-18/3/2022
1.81 % Smith (J Jefferson)130,9971,5671/23/2024
1.60 % Citadel Advisors LLC115,52511,06112/31/2023
1
2
3
4
5
...
10

Precision BioSciences Executives and Management Board

Mr. Michael Amoroso45
Precision BioSciences President, Chief Executive Officer, Director (since 2021)
Compensation 4.37 M
Mr. Alex Kelly56
Precision BioSciences Chief Financial Officer
Compensation 2.38 M
Mr. Dario Scimeca48
Precision BioSciences General Counsel, Secretary
Compensation 1.51 M
Ms. Melinda Brown66
Precision BioSciences Independent Director
Compensation 442,493
Mr. Kevin Buehler65
Precision BioSciences Independent Chairman of the Board
Compensation 324,669
1
2
3

Most common questions regarding Precision BioSciences

What values and corporate philosophy does Precision BioSciences represent?

Precision BioSciences Inc is a biotechnology company that focuses on utilizing its ARCUS genome editing platform to enhance the versatility and efficiency of gene editing. With a strong commitment to next-generation gene therapies, Precision BioSciences aims to address unmet medical needs and transform the lives of patients. The company's corporate philosophy revolves around precision in genome editing, driving innovation in the field of molecular medicine. Precision BioSciences aims to revolutionize the treatment of genetic diseases by delivering safe, effective, and targeted therapies that maximize patient outcomes. With a dedicated team and cutting-edge technology, Precision BioSciences Inc is poised to make significant contributions to the future of genetic medicine.

In which countries and regions is Precision BioSciences primarily present?

Precision BioSciences Inc is primarily present in the United States and operates globally. The company's headquarters is located in Durham, North Carolina, USA. Precision BioSciences focuses on developing and commercializing its proprietary ARCUS genome editing platform, which enables precise and efficient gene edits. With a strong presence in the United States, Precision BioSciences also engages in research collaborations and partnerships on a global scale, collaborating with pharmaceutical and biotechnology companies worldwide. The company's commitment to advancing gene editing technologies extends beyond borders, making it a prominent player in the international market.

What significant milestones has the company Precision BioSciences achieved?

Precision BioSciences Inc, a leading biotechnology company, has achieved several significant milestones. Notably, the company successfully developed and commercialized its proprietary ARCUS genome editing platform, which offers precise and efficient editing of genes. Precision BioSciences also obtained regulatory approval for multiple clinical trials, showcasing its commitment to advancing innovative therapeutics. Furthermore, the company has fostered collaborations and partnerships with renowned institutions and pharmaceutical companies, expanding its research capabilities and potential market reach. With its cutting-edge technology and strong industry presence, Precision BioSciences Inc continues to make remarkable strides in the field of genome editing and holds immense promise for the future.

What is the history and background of the company Precision BioSciences?

Precision BioSciences Inc., a biotechnology company based in Durham, North Carolina, was founded in 2006. The company focuses on developing and commercializing its proprietary genome editing platform called ARCUS. Precision BioSciences utilizes this platform for various applications such as developing transformative gene and cell therapies, creating sustainable food and agriculture solutions, and advancing genetic medicines. The company's ARCUS platform is characterized by its versatility, specificity, and efficacy, enabling precise editing of the genome. Precision BioSciences has established collaborations with renowned organizations to further advance its gene editing capabilities and expand its therapeutic and agricultural product portfolios.

Who are the main competitors of Precision BioSciences in the market?

Prominent competitors of Precision BioSciences Inc in the market include but are not limited to Editas Medicine Inc, Intellia Therapeutics Inc, and CRISPR Therapeutics AG.

In which industries is Precision BioSciences primarily active?

Precision BioSciences Inc is primarily active in the biotechnology industry.

What is the business model of Precision BioSciences?

The business model of Precision BioSciences Inc. revolves around utilizing its proprietary platform called ARCUS to develop gene editing therapies. Precision BioSciences aims to address previously untreatable genetic diseases by using its next-generation genome editing technology. The company focuses on developing and commercializing its gene therapies for various indications to improve patients' lives, having a strong pipeline of therapeutic candidates. Precision BioSciences' business model centers on leveraging its innovative technology to advance precision genome editing solutions and collaborate with partners in the healthcare industry to bring potentially life-changing therapies to patients in need.

What is the P/E ratio of Precision BioSciences 2024?

The Precision BioSciences P/E ratio is -3.59.

What is the P/S ratio of Precision BioSciences 2024?

The Precision BioSciences P/S ratio is 0.47.

What is the AlleAktien quality score of Precision BioSciences?

The AlleAktien quality score for Precision BioSciences is 3/10.

What is the revenue of Precision BioSciences 2024?

The expected Precision BioSciences revenue is 81.18 M USD.

How high is the profit of Precision BioSciences 2024?

The expected Precision BioSciences profit is -10.64 M USD.

What is the business model of Precision BioSciences

Precision BioSciences Inc is a biotechnology company specializing in the development of genetic solutions for healthcare, agriculture, and the energy industry. Founded in 2006, the company is headquartered in Durham, North Carolina. Precision BioSciences' business model is based on the patented ARCUS Genome Editing Technology, which allows for precise and efficient manipulation of genes. The ARCUS platform uses natural proteins called Meganucleases to cut specific DNA sequences in cells. By combining the Meganuclease with an artificial DNA strand, the DNA can be modified at the desired location. The ARCUS technology is applied in various fields to develop innovative solutions. One example is its application in healthcare, where Precision BioSciences develops therapies for rare diseases and cancer. The company works closely with pharmaceutical companies to develop new therapies and conduct clinical trials. Additionally, Precision BioSciences is involved in agriculture, assisting plant breeders in developing plant varieties that are resistant to diseases and extreme weather conditions. The ARCUS technology can also help reduce the use of pesticides and herbicides, thereby protecting the environment. The third sector of Precision BioSciences is the energy industry, where they are working on the development of biofuels. The ARCUS technology can help create new types of biomass that can be used to produce biofuels. Precision BioSciences also offers various products based on the ARCUS technology. These include ARCUS Genome Editing Kits, which provide researchers and scientists with a simple and efficient way to edit genes in a variety of cell types. Additionally, the company offers a proprietary screening system to improve the efficiency and accuracy of gene editing processes. In summary, Precision BioSciences' business model is focused on developing innovative genetic solutions for healthcare, agriculture, and the energy industry. The ARCUS technology provides a precise and effective way to manipulate genes, offering the potential to develop new therapies, plant varieties, and biofuels. The company also offers various products based on the ARCUS technology to improve the efficiency and accuracy of gene editing.

What is the Precision BioSciences dividend?

Precision BioSciences pays a dividend of 0 USD distributed over payouts per year.

How often does Precision BioSciences pay dividends?

The dividend cannot currently be calculated for Precision BioSciences or the company does not pay out a dividend.

What is the Precision BioSciences ISIN?

The ISIN of Precision BioSciences is US74019P1084.

What is the Precision BioSciences WKN?

The WKN of Precision BioSciences is A2PGA1.

What is the Precision BioSciences ticker?

The ticker of Precision BioSciences is DTIL.

How much dividend does Precision BioSciences pay?

Over the past 12 months, Precision BioSciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Precision BioSciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Precision BioSciences?

The current dividend yield of Precision BioSciences is .

When does Precision BioSciences pay dividends?

Precision BioSciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Precision BioSciences?

Precision BioSciences paid dividends every year for the past 0 years.

What is the dividend of Precision BioSciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Precision BioSciences located?

Precision BioSciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Precision BioSciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Precision BioSciences from 9/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/7/2024.

When did Precision BioSciences pay the last dividend?

The last dividend was paid out on 9/7/2024.

What was the dividend of Precision BioSciences in the year 2023?

In the year 2023, Precision BioSciences distributed 0 USD as dividends.

In which currency does Precision BioSciences pay out the dividend?

The dividends of Precision BioSciences are distributed in USD.

All fundamentals about Precision BioSciences

Our stock analysis for Precision BioSciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Precision BioSciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.